Date: Monday 8 April 2019
Time: 0830-1230
Location: Room P7, BCEC
| Monday 8 April 2019 | ||
| Time | Topic | Speaker |
| 0755-0800 | Welcome | Peter Nash |
| 0800-0840 | What’s new in pathogenesis Pso, PsA | Bruce Kirkham |
| 0840-0920 | Biomarkers in PsA – fact or fiction | Oliver Fitzgerald |
| 0920-1000 | Outcome measures in PsA – what should we use? | Katy Leung |
| 1000-1030 | Morning Tea | |
| 1100-1300 | Supervised US scanning of the Lower limbs | All trainers |
| 1030-1100 | Co-morbidities | Lai Shan Tam |
| 1100-1150 | Latest developments in Therapy | Marie Feletar |
| 1150-1225 | Panel discussion – Derm vs Rheum collaboration or Difficult cases 11 | |
| 1225-1230 | Wrap up | Peter Nash |
Panel Discussion
Discuss the roles of:
a. Dermatologists, rheumatologists GPs, nurses and patients in the identification, management and treatment of PsA
b. Soluble biomarkers (e.g. highly sensitive C-reactive protein [hsCRP], osteoprotegerin (OPG), etc.) in identifying psoriasis patients who may develop PsA
c. Various screening tests (e.g. Psoriatic Arthritis Screening and Evaluation [PASE] tool, the Psoriasis Epidemiology Screening Tool [PEST], the Toronto Psoriatic Arthritis Screen [ToPAS] and the Early ARthritis for Psoriatic patients [EARP]) to confirm diagnosis
d. Traditional and new biologic agents (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs], steroid and synthetic disease-modifying antirheumatic drugs [DMARDs], proinflammatory cytokine tumor necrosis factor [TNF]) in the treatment of PsA